Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7189334

CCC(C)Oc1ccc(PC(=O)c2c(C)cccc2C)c(OC(C)CC)c1.[Li]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 4/20 0.34
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ HDAC8 Q9BY41 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ MAPT P10636 1/20 0.33
▸ DHODH Q02127 2/20 0.33
▸ CXCR5 P32302 1/20 0.33
▸ PPARG P37231 2/20 0.32
▸ PPARD Q03181 2/20 0.32
▸ PPARA Q07869 2/20 0.32
▸ GPBAR1 Q8TDU6 1/20 0.32
▸ CYSLTR1 Q9Y271 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ MTNR1A P48039 1/20 0.32
▸ MTNR1B P49286 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189324 0.98 ACACB (0.34) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
Lithium SCHEMBL7181322 0.92 DHODH (0.34) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
Lithium SCHEMBL7179682 0.91 ACACB (0.34) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
SCHEMBL7181314 0.90 DHODH (0.34) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
Lithium SCHEMBL7182005 0.88 DHODH (0.35) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
SCHEMBL7179676 0.88 ACACB (0.34) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
SCHEMBL7175702 0.88 SMN1; SMN2 (0.38) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
Lithium SCHEMBL7183541 0.87 HDAC1 (0.33) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
Lithium SCHEMBL7189019 0.87 MAPT (0.38) ACACBHDAC1HDAC2HDAC8SMN1; SMN2
Lithium SCHEMBL7180737 0.86 ACACB (0.33) ACACBHDAC1HDAC2HDAC8SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ACACB 914/4885HDAC1 1556/4885HDAC2 2156/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ACACB 555/4885HDAC1 1870/4885HDAC2 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.